Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)

Faye Horner, Peck-Lin Lip, Hannah Clark, Randhir Chavan, Ambreen Sarmad, Bushra Mushtaq Birmingham and Midland Eye Centre, Birmingham, UKCorrespondence: Bushra MushtaqBirmingham and Midland Eye Centre, City Hospital, Dudley Road, Birmingham B18 7QH, UKEmail bushramushtaq@nhs.netPurpose: To report th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Horner F, Lip PL, Clark H, Chavan R, Sarmad A, Mushtaq B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	age-related macular degeneration ranibizumab real-world 8 year Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/3fc4a81a682e46cbb8d24242cf2456af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3fc4a81a682e46cbb8d24242cf2456af
record_format	dspace
spelling	oai:doaj.org-article:3fc4a81a682e46cbb8d24242cf2456af2021-12-02T03:25:57ZReal-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)1177-5483https://doaj.org/article/3fc4a81a682e46cbb8d24242cf2456af2019-12-01T00:00:00Zhttps://www.dovepress.com/real-world-visual-and-clinical-outcomes-for-patients-with-neovascular--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Faye Horner, Peck-Lin Lip, Hannah Clark, Randhir Chavan, Ambreen Sarmad, Bushra Mushtaq Birmingham and Midland Eye Centre, Birmingham, UKCorrespondence: Bushra MushtaqBirmingham and Midland Eye Centre, City Hospital, Dudley Road, Birmingham B18 7QH, UKEmail bushramushtaq@nhs.netPurpose: To report the long-term clinical outcomes for patients with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (anti-VEGF) therapy as part of a standardised treatment protocol in a real-world setting.Patients and methods: This is a retrospective audit of all treatment-naïve patients with nAMD who commenced a pro re nata (PRN) treatment regimen of intravitreal Ranibizumab from January to December 2009 and completed 8 years of follow-up in one single-treatment centre. Electronic medical notes were reviewed to evaluate the outcome measures. Outcome measures included progression of visual acuity (VA), central retinal thickness (CRT) and treatment frequency.Results: 95 eyes from 86 patients had complete data for 8 years of follow-up. Baseline median CRT was 295μm [IQR 254–349] and improved to 209μm [IQR 182–254] in year 8 (p<0.001); baseline median VA was 61 ETDRS letters which increased to 70 letters post-loading however was reduced to 55 letters by year 8 (mean VA change from baseline was −9.1 letters); 47.4% had stable or improved vision, 10.5% gained ≥15 letters and 33.7% had lost ≥15 letters. The highest visual gain was achieved after the initial loading-phase, with a subsequent steady decline, 26.3% (compared to baseline 33.4%) achieved driving vision standard. Median injection frequency was 6 (range 3–10) in year 1 and 3 injections (range 0–10) in year 8. 51.6% of eyes required at least one injection each year and only 34.7% required no injections in year 8.Conclusion: Our real-world nAMD treatment cohort using Ranibizumab PRN regimen achieved an encouraging almost 50% stable or improved VA at year 8 and total injections of 31.6 injections per patient over an 8-year period.Keywords: age-related macular degeneration, Ranibizumab, real-world, 8 yearHorner FLip PLClark HChavan RSarmad AMushtaq BDove Medical Pressarticleage-related macular degenerationranibizumabreal-world8 yearOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 2461-2467 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	age-related macular degeneration ranibizumab real-world 8 year Ophthalmology RE1-994
spellingShingle	age-related macular degeneration ranibizumab real-world 8 year Ophthalmology RE1-994 Horner F Lip PL Clark H Chavan R Sarmad A Mushtaq B Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
description	Faye Horner, Peck-Lin Lip, Hannah Clark, Randhir Chavan, Ambreen Sarmad, Bushra Mushtaq Birmingham and Midland Eye Centre, Birmingham, UKCorrespondence: Bushra MushtaqBirmingham and Midland Eye Centre, City Hospital, Dudley Road, Birmingham B18 7QH, UKEmail bushramushtaq@nhs.netPurpose: To report the long-term clinical outcomes for patients with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (anti-VEGF) therapy as part of a standardised treatment protocol in a real-world setting.Patients and methods: This is a retrospective audit of all treatment-naïve patients with nAMD who commenced a pro re nata (PRN) treatment regimen of intravitreal Ranibizumab from January to December 2009 and completed 8 years of follow-up in one single-treatment centre. Electronic medical notes were reviewed to evaluate the outcome measures. Outcome measures included progression of visual acuity (VA), central retinal thickness (CRT) and treatment frequency.Results: 95 eyes from 86 patients had complete data for 8 years of follow-up. Baseline median CRT was 295μm [IQR 254–349] and improved to 209μm [IQR 182–254] in year 8 (p<0.001); baseline median VA was 61 ETDRS letters which increased to 70 letters post-loading however was reduced to 55 letters by year 8 (mean VA change from baseline was −9.1 letters); 47.4% had stable or improved vision, 10.5% gained ≥15 letters and 33.7% had lost ≥15 letters. The highest visual gain was achieved after the initial loading-phase, with a subsequent steady decline, 26.3% (compared to baseline 33.4%) achieved driving vision standard. Median injection frequency was 6 (range 3–10) in year 1 and 3 injections (range 0–10) in year 8. 51.6% of eyes required at least one injection each year and only 34.7% required no injections in year 8.Conclusion: Our real-world nAMD treatment cohort using Ranibizumab PRN regimen achieved an encouraging almost 50% stable or improved VA at year 8 and total injections of 31.6 injections per patient over an 8-year period.Keywords: age-related macular degeneration, Ranibizumab, real-world, 8 year
format	article
author	Horner F Lip PL Clark H Chavan R Sarmad A Mushtaq B
author_facet	Horner F Lip PL Clark H Chavan R Sarmad A Mushtaq B
author_sort	Horner F
title	Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
title_short	Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
title_full	Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
title_fullStr	Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
title_full_unstemmed	Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
title_sort	real-world visual and clinical outcomes for patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: an 8-year observational cohort (amd8)
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/3fc4a81a682e46cbb8d24242cf2456af
work_keys_str_mv	AT hornerf realworldvisualandclinicaloutcomesforpatientswithneovascularagerelatedmaculardegenerationtreatedwithintravitrealranibizumaban8yearobservationalcohortamd8 AT lippl realworldvisualandclinicaloutcomesforpatientswithneovascularagerelatedmaculardegenerationtreatedwithintravitrealranibizumaban8yearobservationalcohortamd8 AT clarkh realworldvisualandclinicaloutcomesforpatientswithneovascularagerelatedmaculardegenerationtreatedwithintravitrealranibizumaban8yearobservationalcohortamd8 AT chavanr realworldvisualandclinicaloutcomesforpatientswithneovascularagerelatedmaculardegenerationtreatedwithintravitrealranibizumaban8yearobservationalcohortamd8 AT sarmada realworldvisualandclinicaloutcomesforpatientswithneovascularagerelatedmaculardegenerationtreatedwithintravitrealranibizumaban8yearobservationalcohortamd8 AT mushtaqb realworldvisualandclinicaloutcomesforpatientswithneovascularagerelatedmaculardegenerationtreatedwithintravitrealranibizumaban8yearobservationalcohortamd8
_version_	1718401724653240320

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)

Ejemplares similares